Natera (NTRA) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Competitive positioning and innovation

• Focused on technology leadership, rapid innovation, and a strong team to maintain a competitive edge in oncology and MRD testing.

• Over 75 peer-reviewed publications and more than 100 ongoing clinical trials support product differentiation.

• Emphasis on user experience, including insurance network coverage, EMR connectivity, and fast turnaround times for patient setup and monitoring.

• Large commercial and medical affairs teams drive adoption and support.

R&D investment and product pipeline

• Significant R&D investment, with $400 million planned, supports innovation and ancillary product development.

• Updates on new product launches and enhancements are expected soon.

• CRC screening program's initial readout is expected this year, with a large prospective sample cohort and potential for rapid expansion.

• Data-driven strategy will determine further investment in CRC screening, with minimal financial impact expected in 2025-2026.

Clinical data and upcoming milestones

• Anticipated CIRCULATE GALAXY readout at ESMO will provide 36-month follow-up data, including overall survival and DFS in 2,000 patients.

• Data will inform chemotherapy benefit in Signatera-positive and -negative cohorts, with implications for clinical practice and pharma partnerships.

• ALTAIR data set and other prospective studies will contribute to guideline support, with incremental milestones expected.